Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytokinetics, Incorporated (CYTK : NSDQ)

• Company Description    Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Number of Employees: 498

• Price / Volume Information    Yesterday's Closing Price: $53.32 Daily Weekly Monthly 20 Day Moving Average: 2,601,949 shares Shares Outstanding: 119.66 (millions) Market Capitalization: $6,380.12 (millions) Beta: 0.62 52 Week High: $59.39 52 Week Low: $29.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 37.71% 35.22% 12 Week 62.91% 47.91% Year To Date 13.35% 1.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 OYSTER POINT BOULEVARD - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-624-3000 fax: 650-624-3010 investor@cytokinetics.com http://www.cytokinetics.com

• General Corporate Information    Officers Robert I. Blum - President; Chief Executive Officer and Director John T. Henderson - Chairman Sung H. Lee - Executive Vice President; Chief Financial Officer Robert E. Landry - Director B. Lynne Parshall - Director Peer Information Cytokinetics, Incorporated (CORR.) Cytokinetics, Incorporated (RSPI) Cytokinetics, Incorporated (CGXP) Cytokinetics, Incorporated (BGEN) Cytokinetics, Incorporated (GTBP) Cytokinetics, Incorporated (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23282W605 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 119.66 Most Recent Split Date: 6.00 (0.17:1) Beta: 0.62 Market Capitalization: $6,380.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 28.66% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 74.41 EPS Growth vs. Year Ago Period: 14.50% vs. Previous Quarter: 17.65% Sales Growth vs. Year Ago Period: 26,714.86% vs. Previous Quarter: 4,128.56% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -45.52 03/31/25 - -43.75 12/31/24 - -45.62 Current Ratio 06/30/25 - 6.76 03/31/25 - 5.99 12/31/24 - 6.17 Quick Ratio 06/30/25 - 6.76 03/31/25 - 5.99 12/31/24 - 6.17 Operating Margin 06/30/25 - -707.17 03/31/25 - -3,201.47 12/31/24 - -3,191.11 Net Margin 06/30/25 - -707.17 03/31/25 - -3,201.47 12/31/24 - -3,191.11 Pre-Tax Margin 06/30/25 - -707.17 03/31/25 - -3,201.47 12/31/24 - -3,191.11 Book Value 06/30/25 - -3.09 03/31/25 - -2.24 12/31/24 - -1.15 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©